Skip to content

Reverberation Effects on MED-EL Recipients

The Effects of Reverberation on Speech Understanding in MED-EL Cochlear Implant Recipients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03143296
Enrollment
10
Registered
2017-05-08
Start date
2018-08-16
Completion date
2021-04-16
Last updated
2021-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hearing Loss, Sensorineural

Brief summary

The purpose of this study is to investigate speech understanding in simulated reverberant environments with MED-EL cochlear implant recipients.

Detailed description

The study will determine if electrode length and coding strategy effect performance. The investigator will also study performance over time with new recipients.

Interventions

OTHERSimulated reverberant environment

Reverberant environments simulate real-life situations mimicking a living room, classroom and auditorium. Each simulation lasts up to 2 hours.

Sponsors

Med-El Corporation
CollaboratorINDUSTRY
University of Miami
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* MED-EL current cochlear implant recipients of the Flex 24 or 28 will be included * Minimum of 6 months experience with their cochlear implant * Minimum of 10 new adult Med-El recipients of the Flex 24 or Flex 28 electrodes * Patient at the University of Miami

Exclusion criteria

* Adults unable to consent * Individuals who are not yet adults (infants, children, teenagers)

Design outcomes

Primary

MeasureTime frameDescription
Speech PerformanceUp to six monthsSpeech performance recorded as percent correct compared to different electrode lengths.
Coding strategyTwo hoursSpeech scores, in percent correct, recorded from simulated reverberant speech tests will be compared between fine structure and envelope coding strategies.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026